About this episode
Novo Nordisk, the pharmaceutical company behind popular GLP-1 medications like Wegovy and Ozempic, recently announced that its phase 3, two-year trial examining GLP-1 medications for Alzheimer's failed to produce a significant reduction in disease progression.While these results are discouraging, they may have revealed something vital about Alzheimer’s treatment.In this video, Dr. Bret Scher breaks down the recent failure of Novo Nordisk’s evoke and evoke+ trials and what it teaches us about the limitations of a drug-only approach to Alzheimer’s treatment.Key topics covered:Why GLP-1s may not be enough for Alzheimer’sThe link between glucose metabolism and brain energy failureHow ketones offer an alternative fuel for the brainEarly research on ketogenic therapy for cognitive impairmentWhy nutritional interventions deserve more scientific attentionWith Alzheimer’s affecting millions and costing billions, it’s time to shine a light on metabolic strategies that directly support brain energy, reduce inflammation, and improve cognitive function.🧠 Explore our full playlist on ketogenic therapy for Alzheimer’s and cognitive decline: https://www.youtube.com/playlist?list=PLzWI83-NWCL4f7uVRIWUHCC2nF6t_5DLw#MetabolicMind #KetogenicTherapy #AlzheimersExpert Featured:Dr. Bret ScherBaszucki Group Medical Directorhttps://x.com/bschermdResources Mentioned:Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progressionhttps://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916462#Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the UShttps://doi.org/10.1002/alz.14313Brain energy rescue with ketones improves cognitive outcomes in MCIhttps://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.059627Randomized crossover trial of a modified ketogenic diet in Alzheimer's
